Impact of Guideline-Driven Approach in Follow-Up of Long-Term Complications After Allogeneic Hematopoietic Cell Transplant: Single Center Experience

2020 ◽  
Vol 18 (3) ◽  
pp. 359-367
Author(s):  
Ali Hakan Kaya ◽  
Sinem Namdaroğlu ◽  
Ömür Kayıkcı ◽  
Alparslan Merdin ◽  
Hikmettullah Batgi ◽  
...  
Keyword(s):  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Single Center ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant ◽  
Single Center Experience

Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience

2018 ◽  
Vol 59 (11) ◽  
pp. 2727-2730 ◽  
Author(s):  
Bhagirathbhai R. Dholaria ◽  
William A. Hammond ◽  
Vivek Roy ◽  
Taimur Sher ◽  
Prakash Vishnu ◽  
...  
Keyword(s):  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Single Center ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant ◽  
Single Center Experience

scholarly journals Lung Function and Long-Term Complications after Allogeneic Hematopoietic Cell Transplant

2010 ◽  
Vol 16 (1) ◽  
pp. 53-61 ◽  
Author(s):  
Eric C. Walter ◽  
Mauricio Orozco-Levi ◽  
Alba Ramirez-Sarmiento ◽  
Afonso Vigorito ◽  
Paulo V. Campregher ◽  
...  
Keyword(s):  
Lung Function ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant

Antipneumococcal Seroprotection Years After Vaccination in Allogeneic Hematopoietic Cell Transplant Recipients

2019 ◽  
Vol 71 (8) ◽  
pp. e301-e307
Author(s):  
Christine Robin ◽  
Mathilde Bahuaud ◽  
Rabah Redjoul ◽  
Mohamed Jeljeli ◽  
Mathieu Leclerc ◽  
...  
Keyword(s):  
Chronic Gvhd ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Igg Antibody ◽  
Seroprotection Rate ◽  
Allogeneic Hematopoietic Cell Transplant ◽  
Cord Blood Unit ◽  
Antibody Titers

Abstract Background International guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 months after transplant, giving 3 doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of 23-valent pneumococcal polysaccharide vaccine (PSV23) or a fourth PCV dose in the case of graft-versus-host disease (GvHD). However, the long-term immunity after this regimen is unknown, and there is no recommendation from 24 months after transplant regarding boosts. Our objective was to assess the antipneumococcal antibody titers and seroprotection rates of allogeneic HCT recipients years after different schedules of vaccination. Methods We assessed 100 adult HCT recipients a median of 9.3 years (range: 1.7–40) after transplant. All patients had received at least one dose of PCV and were assessed for antipneumococcal immunoglobulin G (IgG) antibody titers against the 7 serotypes shared by PCV7, PCV13, and PSV23. Sixty-six percent of the patients had been vaccinated according to the current guidelines. Results Considering an IgG titer ≥ 0.35 µg/mL as protective for each serotype, the seroprotection rate was 50% for 7/7 serotypes and 70% for 5/7 serotypes, with no differences between the different vaccination schedules. The lack of seroprotection was associated with a transplant performed not in complete remission or from a cord-blood unit, a relapse after transplant, or chronic GvHD at assessment. Conclusion Because only half of the vaccinated patients had long-term protection, pending prospective studies defining the best boost program after the initial one, we recommend the assessment of specific IgG titers starting from 24 months to decide for further doses.

Sign in / Sign up

Export Citation Format

Share Document